During its 20 years of life, Primm has become a leading international company in the area of biotechnology services, and several qualified industrial and academic laboratories in United States and Europe have chosen Primm as their partner for selected biotechnological services. In order to stay at the forefront of the technological and scientific evolution of research activities, Primm is always investing in new technical processes and in the automation of the manufacturing steps. Through our internal know-how, and a broad and heterogeneous portfolio of research tools and services, we can efficiently complement the research activities of the customers, providing reliable and cost-effective technical solutions. Our customers are always followed with high professional skills and with the necessary technological support required for a successful collaboration.
Primm today is not only an efficient biotech services organization but during the years it has invested its own resources in Biomedical Research and Development activities with potential industrial outcome. Several projects in different areas have been carried out in close collaboration with major companies and academic institutions.
Research activities at Primm are related to the internal know how that the company has developed in the past years to supply state-of-the-art custom services to the scientific community. In particular, the expertise developed in the field of Antibodies and Peptides has led to the spin off of very innovative projects that are progressing in the development pipeline and whose results are opening new industrial opportunities for applications in the area of Oncology and Neurodegeneration. Today Primm is actively engaged in the following research projects:
Identification and development of novel tumor biomarkers through the exploitation of Antibody and Protein Libraries generated from unknown human genes
Design and development of new bio-active peptides able to display Nerve Growth Factor-like activity for the treatment of neurodegenerative diseases
Development of efficient technologies for the production of recombinant proteins of pharmaceutical interest
In order to strengthen its research activities, Primm has concentrated the specific projects in dedicated companies belonging to our group. The development of novel biomarkers for applications in Oncology is actively carried out by EXTERNAUTICS SpA, a biotech company based in Siena, Italy and founded in collaboration with biotech investment funds.
The pharmaceutical development of novel peptides for the treatment of neurodegenerative disease is brought forward by BLUEPRINT BIOTECH srl, based in Milan and founded in collaboration with the University of Milano Bicocca.